The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Sigrun Hallmeyer
No relevant relationships to disclose
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Thuy Anh Sorof
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Yong Mun
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Shiyao Liu
Employment or Leadership Position - Genentech
Sarang Abhyankar
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Geoffrey Thomas Gibney
Consultant or Advisory Role - Roche/Genentech
Igor Puzanov
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche